Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Boehringer Ingelheim
>
BREZTRI launch
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6350022"]The plan is for is to continue to differentiate triple from LAMA/LABA class and then to further differentiate Stiolto from the rest of the LAMA/LABAs. It is the current plan and this holds true regardless of what happens in the triple class. There is value in the lama/laba class and guidelines support this position. So quit whining and do what you’re paid to do.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6350022"]The plan is for is to continue to differentiate triple from LAMA/LABA class and then to further differentiate Stiolto from the rest of the LAMA/LABAs. It is the current plan and this holds true regardless of what happens in the triple class. There is value in the lama/laba class and guidelines support this position. So quit whining and do what you’re paid to do.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Boehringer Ingelheim
>
BREZTRI launch
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Boehringer Ingelheim
>
BREZTRI launch
>